Bcl-2

You have access
Targeting BCL-2 as a Therapeutic Strategy for Primary ^p210BCR-ABL1-positive B-ALL Cells
MICHELE MASSIMINO, ELENA TIRRÒ, STEFANIA STELLA, MARIA STELLA PENNISI, SILVIA RITA VITALE, ADRIANA PUMA, CHIARA ROMANO, SANDRA DI GREGORIO, MARIA ANNA ROMEO, FRANCESCO DI RAIMONDO and LIVIA MANZELLA

In Vivo March 2020, 34 (2) 511-516; DOI: https://doi.org/10.21873/invivo.11802
You have access
Association of Pro-apoptotic Bad Gene Expression Changes with Benign Thyroid Nodules
NURDAN GÜL, BERNA TEMEL, DURAN USTEK, SEMA SIRMA-EKMEKÇI, YERSU KAPRAN, FATIH TUNCA, YASEMIN GILES-ŞENYÜREK, UĞUR ÖZBEK and FARUK ALAGÖL

In Vivo May 2018, 32 (3) 555-559;
You have access
Additional Compensatory Mechanisms Altering Antisense Oligonucleotide Suppression of BCL2: Effects upon AKT1 and STAT3
MARVIN RUBENSTEIN, COURTNEY M. P. HOLLOWELL and PATRICK GUINAN

In Vivo September 2014, 28 (5) 867-870;
You have access
No Compensation in CD44 Stem Cell Marker Following BCL-2 Suppression By Antisense Oligonucleotides
MARVIN RUBENSTEIN, COURTNEY M.P. HOLLOWELL and PATRICK GUINAN

In Vivo March 2013, 27 (2) 251-256;
You have access
No Compensation in VEGF Expression Follows Antisense Suppression of BCL-2 Activity
MARVIN RUBENSTEIN, COURTNEY M.P. HOLLOWELL and PATRICK GUINAN

In Vivo November 2012, 26 (6) 937-940;

Main menu